Project description
A disruptive treatment for glioblastoma
Glioblastoma multiforme (GBM) is the highest unmet need in oncology worldwide with dismal prognosis and limited treatment options. Currently, there are no targeted therapies available for GBM. Funded by the European Innovation Council, the CureGLIO project will test the clinical safety and efficacy of a novel epigenetic therapy against the TET2 enzyme which reverses chemical modifications in DNA in cancer cells. This seems to activate the DNA damage response and kill cancer cells. The GLIX1 small molecule has been successfully tested in animals, resulting in tumour mass reduction and even total remission. Clinical validation of this promising therapy will bring hope to GBM patients.
Objective
Glioblastoma Multiform (GBM) patients usually die 12-18 months after diagnosis, with a 5-year survival rate of 6.8%. There are only 5 therapies approved to treat GBM and all of them provide marginal improvements of <9 months to patients’ survival. With a clinical pipeline that is constantly failing (last approval in 2004) and the lack of effective therapies, GBM remains the highest unmet need in oncology.
After years of research, we discovered the GLIX family, which targets a newly discovered mechanism that is deregulated in cancer cells. GLIX1 was more effective than the current standard of care at killing several GBM cell lines. In vivo studies showed tumour regression in 100% of mice, with a tumour growth inhibition of 94%. With such promising results and an experienced team, GLIX1 is now ready for clinical validation. The support from the EIC will help us to prove the clinical safety and efficacy of GLIX1 and make it globally available through licensing to a large pharma company.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
You need to log in or register to use this function
Programme(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Funding Scheme
EIC-ACC - EIC-ACCCoordinator
0349 OSLO
Norway
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.